Royalty Pharma plc
RPRX
$35.42
$0.270.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.83% | -4.28% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.83% | -4.28% | |||
| Cost of Revenue | -60.40% | -177.51% | |||
| Gross Profit | 12.54% | 61.87% | |||
| SG&A Expenses | 132.42% | 63.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 938.80% | -85.32% | |||
| Operating Income | -57.92% | 47.76% | |||
| Income Before Tax | -79.09% | 29.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -79.09% | 29.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 69.01% | -54.66% | |||
| Net Income | -87.34% | 14.47% | |||
| EBIT | -57.92% | 47.76% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -86.97% | 54.82% | |||
| Normalized Basic EPS | -59.65% | 86.72% | |||
| EPS Diluted | -86.99% | 54.20% | |||
| Normalized Diluted EPS | -59.69% | 40.69% | |||
| Average Basic Shares Outstanding | -2.75% | -26.06% | |||
| Average Diluted Shares Outstanding | -2.73% | -1.85% | |||
| Dividend Per Share | 0.00% | 4.76% | |||
| Payout Ratio | 6.72% | -0.11% | |||